 |
NHMRC Clinical Trials Centre |
 |
 |
 |
 |
 |
 |
 |
 |
||
| Other trials |
Trials > ASPIRE
Aspirin to prevent recurrent venous thromboembolism
(ASPIRE)
Project manager–trial coordinator: Rebecca Mister |
|
||
|
Each year, an estimated 20 000 Australians develop deep-vein thrombosis (a blood clot) or pulmonary embolism (a clot that travels to the lungs) for the first time. A third have no known cause. The average age for a first episode is 65 years. Each year, as many as 5000 in Australia have a further episode, and several hundred die of fatal pulmonary embolism. |
|||
| There is a great need to identify a simple, safe and effective way to prevent further thrombosis where the cause of the thrombosis is not known. This Australian designed and initiated study is addressing a scientific question of major public health importance and has the potential to prevent thousands of patients worldwide from experiencing recurrent venous thromboembolism. | |||
| The ASPIRE trial will test the use of low-dose aspirin to prevent further clotting. | |||
| The trial is multicentre, randomised, double-blind, placebo-controlled trial examining the efficacy and safety of low-dose aspirin after treatment with oral anticoagulant drugs (heparin or an effective alternative and warfarin) in preventing further venous thrombosis and pulmonary embolism. | |||
|
Study drug |
|||
| • | 100 mg aspirin (acetylsalicylic acid) | ||
| Main outcome measure | |||
| • | objectively diagnosed symptomatic venous thromboembolism or fatal pulmonary embolism | ||
|
Accrual: 3000 patients followed up for 2 to 4 years |
|||
| Funding: NHMRC, Bayer, Australian Society for Thrombosis and Haemostasis, NSW Department of Health | |||
| The pilot phase of this study ran from May 2003 until July 2004. The main study is currently under way. | |
||